Doxorubicin-Loaded Liposome with the Function of "Killing Two Birds with One Stone" against Glioma

Area of Science:

• Nanomedicine
• Neuro-oncology
• Drug Delivery Systems

Background:

• The blood-brain barrier (BBB) presents a significant challenge in glioma treatment.
• Conventional chemotherapy for glioma often results in severe side effects.
• Nanomaterial-based drug delivery vehicles show promise for improved glioma therapy.

Purpose of the Study:

• To develop and evaluate a dual-targeting liposomal delivery system (LS-DOX) for treating glioma.
• To utilize the peptide SS31 for enhanced BBB penetration and mitochondria-specific targeting.
• To assess the efficacy and safety of LS-DOX in an in situ glioma model.

Main Methods:

• Preparation of doxorubicin (DOX)-loaded liposomes modified with SS31 peptide.
• In vitro characterization of liposomes for drug encapsulation, loading capacity, biocompatibility, and stability.
• Evaluation of BBB crossing and glioma targeting capabilities.
• Assessment of therapeutic efficacy and toxicity in nude mice with in situ glioma.

Main Results:

• LS-DOX exhibited high drug encapsulation and loading capacity with good in vitro stability and biocompatibility.
• The liposomes effectively crossed the BBB and accumulated in gliomas.
• SS31-mediated mitochondria targeting enhanced cellular uptake.
• LS-DOX demonstrated significant therapeutic effects in vivo with no obvious toxicity.

Conclusions:

• The developed dual-targeting liposomal system (LS-DOX) is effective for glioma treatment.
• This nanomedicine approach offers a promising, safe, and efficient strategy for overcoming BBB limitations in glioma therapy.
• LS-DOX provides a novel alternative for clinical glioma treatment and a valuable reference for future research.